Diagnosis: Hydroxychloroquine-induced pigmentation
A 54-year-old female with a history of systemic lupus erythematosus presents with slate-gray hyperpigmented patches on her shins, developed after long-term hydroxychloroquine treatment. The pigmentation is asymptomatic and has been persistent despite discontinuation of the medication. This case highlights the importance of recognizing drug-induced pigmentation in patients on long-term antimalarial therapy.
A 54-year-old female with a history of systemic lupus erythematosus presents with slate-gray hyperpigmented patches on her shins. These patches developed gradually over the past year following prolonged use of hydroxychloroquine for her condition. Upon examination, the lesions are well-defined and localized, with no associated pruritus or pain.Location: Bilateral shinsColor: Slate-gray pigmentationBorders: Well-defined and irregularTexture: Flat, non-scalySymptoms: Asymptomatic
The patient reports that the hyperpigmented patches began appearing approximately one year after starting hydroxychloroquine, which she has been taking for five years to manage her lupus. She denies any recent changes in her medication regimen or other new exposures. There is no history of skin trauma or other dermatologic conditions. Family history is significant for autoimmune diseases, but no history of similar skin changes. She has no known allergies and is a non-smoker.Onset: Hyperpigmentation noticed 1 year after starting hydroxychloroquineDuration: 1 yearPrior treatments: Discontinued hydroxychloroquine 6 months agoPast medical history: Systemic lupus erythematosusFamily history: Autoimmune diseasesSocial history: Non-smoker, no significant sun exposure
Acute / First-Line ManagementDiscontinue hydroxychloroquine to prevent further pigmentation.Consider topical agents such as hydroquinone 2% to 4% cream for cosmetic improvement.Educate the patient about sun protection using broad-spectrum SPF 30 or higher to prevent exacerbation.Workup and Diagnostic ConfirmationClinical diagnosis based on characteristic appearance of the pigmentation.Consider a skin biopsy if there is uncertainty about the diagnosis or if atypical features are present.Perform serum drug levels if necessary to confirm hydroxychloroquine use.Long-Term ManagementMonitor for resolution of pigmentation after discontinuation of hydroxychloroquine.Follow-up every 3-6 months to assess for any changes in skin condition.Consider referral to a dermatologist for persistent or extensive cases.
Drug-induced pigmentation: Includes medications like minocycline and amiodarone; characterized by a history of exposure to the drug and specific pigmentation patterns.Chronic venous stasis: Can present with hyperpigmented patches on the lower extremities; associated with swelling and varicosities.Melasma: Often presents as symmetric facial pigmentation; typically associated with hormonal changes or sun exposure.Post-inflammatory hyperpigmentation: Follows skin injury or inflammation; may have a history of dermatitis or trauma.Dermatologic conditions: Conditions like lichen planus pigmentosus can also cause pigmentation but usually have other distinct clinical features.Acquired bilateral nevus of Ota-like macules: Presents with slate-gray pigmentation, usually on the face; more common in individuals of Asian descent.Argyria: Caused by silver exposure; presents with a bluish-gray discoloration, typically more diffuse.
High-Yield PearlsHydroxychloroquine: Commonly used for autoimmune conditions, but long-term use can lead to unique cutaneous side effects.Drug-induced pigmentation: Recognizing the pattern and history of medication use is crucial for diagnosis.Management: Discontinuation of the offending agent is often the first step in treatment.Monitoring: Follow-up is essential to assess resolution of pigmentation and ensure no other dermatological issues arise.Patient education: Informing patients about potential side effects of medications can enhance compliance and vigilance.Understanding drug-induced pigmentation is critical in the management of patients on long-term systemic therapies.
Tags: hydroxychloroquine, drug pigmentation